ANIX Stock Forecast: Anixa Biosciences, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$2.60
−4.06% on the day

The median 12-month analyst price target for Anixa Biosciences, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 18 Nov 2026 — in the upper half.

Market cap
$92.8M
Ticker Nerd rank
61/ 100
Median analyst target
$9.00
Analysts covering
3
Revenue$0.0
Operating income−$2.7M
Net income−$2.6M
Free cash flow−$1.8M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−0.4%
YTD
−16.7%
1Y
−40.2%
From 52W high
−50.2%
From 52W low
+10.6%
$2.35
$5.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Anixa Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
61/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
83
Volatility
68
Accruals
65
Issuance
49
Revisions
48
Growth
44
Quality
43
Momentum
40

Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (40): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ANIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26ANIXHigh $14.00Median $9.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$6.00
Low
$9.00
Median
$14.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
30 June 2026D. Boral CapitalAssumesBuy$10
8 Apr 2026D. Boral CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
4 Feb 2026D. Boral CapitalMaintainsBuy—
12 Dec 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
11 Sept 2025HC Wainwright & Co.ReiteratesBuy—
9 Sept 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
10 Apr 2025D. Boral CapitalMaintainsBuy—
26 Mar 2025D. Boral CapitalMaintainsBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025Maxim GroupInitiatesBuy—
18 Feb 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANIX.

Market Radar

This page is one stock. Monday covers all of them.

ANIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ANIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Anixa Biosciences, Inc. returned −40.2% against +9.2% for the S&P 500, dividends included.

ANIX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26ANIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
6.4×

Cheaper than 14% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−73.2%

Higher than 17% of US stocks

Return on assets
−41.9%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anixa Biosciences, Inc. has a market value of $92.8M and an enterprise value of $77.9M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$10.5M.

  • Free cash flow in the twelve months to 31 July 2026: −$7.4M.

  • Shares outstanding: 34.6M.

  • Anixa Biosciences, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 19 Nov 2026

Data provided by Twelve Data

Peers

ANIX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANIXAnixa Biosciences, Inc.$92.8M61
EQEquillium, Inc.$90.6M52
ZURAZura Bio Ltd.$91.6M15
HURATuHURA Biosciences, Inc.$90.1M24
PMVPPMV Pharmaceuticals, Inc.$92.1M59
RANIRani Therapeutics Holdings, Inc.$88.4M63
VANIVivani Medical, Inc.$94.7M44

Take a look at ANIX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Anixa Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ANIX

What is the ANIX stock price forecast for 2026-2027?

The median 12-month analyst price target for Anixa Biosciences, Inc. is $9, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIX stock a buy right now?

Of the 3 analysts covering Anixa Biosciences, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anixa Biosciences, Inc. 61 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIX?

As at 18 Nov 2026, Anixa Biosciences, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).

Will ANIX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $9, and Ticker Nerd's factor model ranks Anixa Biosciences, Inc. 61 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIX stock forecast for 2030?

No analyst covering Anixa Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.

How has ANIX stock performed over the past year?

Anixa Biosciences, Inc. returned -40.2% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anixa Biosciences, Inc. do?

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors.

Company

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors. Its work includes vaccine platforms designed to stimulate immune responses against cancer-related targets and a CAR-T-based therapeutic approach aimed at oncology applications. Anixa Biosciences also explores complementary diagnostics and related research programs that support early detection and cancer management. Headquartered in San Jose, California, Anixa Biosciences serves the biotechnology and oncology markets through a pipeline of current products and development programs that address unmet needs in cancer care.

CEO Dr. Amit Kumar Ph.D. · 4 employees · United States · https://www.anixa.com